강스템바이오텍

217730KOSDAQ기초 의약물질 제조업

53.7 / 100

Reference Date: 2026-07-24

Financial Score13.5 / 40

News Sentiment20.2 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but PBR raises overvaluation concerns. Slightly down 3.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Kansstem Biotech, established in 2010, specializes in developing and manufacturing stem cell therapies, with core businesses in stem cell treatments and cosmetics. The stem cell division focuses on therapies for conditions like atopic dermatitis and rheumatoid arthritis, while the cosmetics division sells stem cell-derived products through online channels. The company also develops new drugs based on exosome technology for wound healing and hair loss.

Number of Employees

172people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

3.00Industry Average 1.260.0Point

2.4x industry avg (risky)

ROE

-18.65Industry Average -6.033.5Point

3.1x industry avg (excellent)

Debt Ratio

5.98Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -29.2% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 7Neutral 1Negative 0Average Sentiment Score 80.6

Positive
강스템바이오텍, 내방 빅파마 유상고객 전환…오가노이드 반복수주 관...
강스템바이오텍이 글로벌 제약사와의 물질이전평가계약을 유상고객으로 전환하며, 오가노이드 기반 신약 개발의 국제적 인정을 받았다.
Positive
강스템바이오텍, 글로벌 톱5 제약사와 오가노이드 평가 계약
강스템바이오텍이 글로벌 최고 제약사와의 계약으로 신약 후보물질의 상업적 잠재력이 크게 상승할 것으로 기대됩니다.
Positive
강스템바이오텍, 서울대서 ‘3차원 피부 어셈블로이드’ 기술 도입
강스템바이오텍이 서울대와의 기술 도입으로 혁신적인 피부 모델 기술을 확보하여 미래 의료 기술 발전에 긍정적 영향 기대.

Detailed Momentum

52-week position3.0Point

52w lower range (29%)

Current 2,200Won52-week high 4,61552-week low 1,171

1-month return2.0Point

1m -3.30% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral투자판단관련주요경영사항 (기술도입 계약 체결)2026-07-15